Meta Biomed Co. Ltd (059210) - Net Assets
Based on the latest financial reports, Meta Biomed Co. Ltd (059210) has net assets worth ₩121.24 Billion KRW (≈ $82.16 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩180.11 Billion ≈ $122.06 Million USD) and total liabilities (₩58.87 Billion ≈ $39.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Meta Biomed Co. Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩121.24 Billion |
| % of Total Assets | 67.31% |
| Annual Growth Rate | 6.93% |
| 5-Year Change | 94.54% |
| 10-Year Change | 83.48% |
| Growth Volatility | 11.16 |
Meta Biomed Co. Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Meta Biomed Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 059210 total assets for the complete picture of this company's asset base.
Annual Net Assets for Meta Biomed Co. Ltd (2011–2024)
The table below shows the annual net assets of Meta Biomed Co. Ltd from 2011 to 2024. For live valuation and market cap data, see Meta Biomed Co. Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩93.34 Billion ≈ $63.25 Million |
+28.46% |
| 2023-12-31 | ₩72.66 Billion ≈ $49.24 Million |
+19.92% |
| 2022-12-31 | ₩60.59 Billion ≈ $41.06 Million |
+3.89% |
| 2021-12-31 | ₩58.32 Billion ≈ $39.52 Million |
+21.56% |
| 2020-12-31 | ₩47.98 Billion ≈ $32.51 Million |
-9.93% |
| 2019-12-31 | ₩53.27 Billion ≈ $36.10 Million |
+6.60% |
| 2018-12-31 | ₩49.97 Billion ≈ $33.86 Million |
+8.60% |
| 2017-12-31 | ₩46.01 Billion ≈ $31.18 Million |
-10.81% |
| 2016-12-31 | ₩51.59 Billion ≈ $34.96 Million |
+1.42% |
| 2015-12-31 | ₩50.87 Billion ≈ $34.47 Million |
+15.08% |
| 2014-12-31 | ₩44.20 Billion ≈ $29.96 Million |
-0.75% |
| 2013-12-31 | ₩44.54 Billion ≈ $30.18 Million |
+8.93% |
| 2012-12-31 | ₩40.89 Billion ≈ $27.71 Million |
+4.71% |
| 2011-12-31 | ₩39.05 Billion ≈ $26.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Meta Biomed Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4712737321000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩47.13 Billion | 50.49% |
| Common Stock | ₩11.93 Billion | 12.78% |
| Other Components | ₩34.28 Billion | 36.73% |
| Total Equity | ₩93.34 Billion | 100.00% |
Meta Biomed Co. Ltd Competitors by Market Cap
The table below lists competitors of Meta Biomed Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Suprema HQ Inc
KQ:094840
|
$70.37 Million |
|
Genie Music Corporation
KQ:043610
|
$70.38 Million |
|
Universal Inc
TW:1325
|
$70.39 Million |
|
Drb Holding
KO:004840
|
$70.40 Million |
|
Grupo Mexicano de Desarrollo S.A.B
MX:GMD
|
$70.36 Million |
|
Campina Ice Cream Industry Tbk PT
JK:CAMP
|
$70.35 Million |
|
Genesem Inc
KQ:217190
|
$70.33 Million |
|
Prolific Technology
TWO:6233
|
$70.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Meta Biomed Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 70,047,571,260 to 93,338,757,170, a change of 23,291,185,910 (33.3%).
- Net income of 22,402,486,140 contributed positively to equity growth.
- Dividend payments of 457,422,160 reduced retained earnings.
- Share repurchases of 140,738,110 reduced equity.
- Other factors increased equity by 1,486,860,040.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩22.40 Billion | +24.0% |
| Dividends Paid | ₩457.42 Million | -0.49% |
| Share Repurchases | ₩140.74 Million | -0.15% |
| Other Changes | ₩1.49 Billion | +1.59% |
| Total Change | ₩- | 33.25% |
Book Value vs Market Value Analysis
This analysis compares Meta Biomed Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.08x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.85x to 1.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2394.96 | ₩4420.00 | x |
| 2017-12-31 | ₩2139.63 | ₩4420.00 | x |
| 2018-12-31 | ₩2142.03 | ₩4420.00 | x |
| 2019-12-31 | ₩2289.36 | ₩4420.00 | x |
| 2020-12-31 | ₩2095.01 | ₩4420.00 | x |
| 2021-12-31 | ₩2546.74 | ₩4420.00 | x |
| 2022-12-31 | ₩2649.24 | ₩4420.00 | x |
| 2023-12-31 | ₩3062.71 | ₩4420.00 | x |
| 2024-12-31 | ₩4088.23 | ₩4420.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Meta Biomed Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 24.00%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 23.82%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.90x
- Recent ROE (24.00%) is above the historical average (3.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 3.11% | 4.35% | 0.50x | 1.42x | ₩-2.62 Billion |
| 2012 | 5.85% | 5.20% | 0.43x | 2.60x | ₩-1.65 Billion |
| 2013 | 4.99% | 3.42% | 0.54x | 2.69x | ₩-2.18 Billion |
| 2014 | -11.53% | -8.07% | 0.53x | 2.68x | ₩-9.25 Billion |
| 2015 | 1.58% | 1.17% | 0.60x | 2.24x | ₩-4.28 Billion |
| 2016 | 1.24% | 0.97% | 0.55x | 2.33x | ₩-4.52 Billion |
| 2017 | -8.92% | -6.28% | 0.55x | 2.60x | ₩-8.71 Billion |
| 2018 | -2.30% | -2.18% | 0.54x | 1.96x | ₩-6.15 Billion |
| 2019 | 6.28% | 5.63% | 0.57x | 1.94x | ₩-1.98 Billion |
| 2020 | -8.53% | -8.67% | 0.44x | 2.25x | ₩-8.89 Billion |
| 2021 | 16.33% | 16.20% | 0.57x | 1.77x | ₩3.69 Billion |
| 2022 | 4.34% | 3.81% | 0.57x | 2.00x | ₩-3.43 Billion |
| 2023 | 14.38% | 12.12% | 0.64x | 1.86x | ₩3.07 Billion |
| 2024 | 24.00% | 23.82% | 0.53x | 1.90x | ₩13.07 Billion |
Industry Comparison
This section compares Meta Biomed Co. Ltd's net assets metrics with peer companies in the Healthcare Equipment & Supplies industry.
Industry Context
- Industry: Healthcare Equipment & Supplies
- Average net assets among peers: $71,007,955,869
- Average return on equity (ROE) among peers: 1.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Meta Biomed Co. Ltd (059210) | ₩121.24 Billion | 3.11% | 0.49x | $70.37 Million |
| InBody Co.Ltd (041830) | $139.69 Billion | 14.62% | 0.11x | $269.54 Million |
| MEDIANA Co.Ltd (041920) | $68.31 Billion | 16.46% | 0.12x | $121.88 Million |
| Value Added Technology Co. Ltd (043150) | $113.02 Billion | 8.59% | 1.12x | $228.41 Million |
| MEKICS Co Ltd (058110) | $5.08 Billion | -53.33% | 3.81x | $10.10 Million |
| INFINITT Healthcare Co. Ltd (071200) | $56.06 Billion | 3.95% | 0.41x | $96.80 Million |
| i-SENS Inc (099190) | $68.44 Billion | 12.78% | 0.34x | $197.36 Million |
| Sewoon Medical Co. Ltd (100700) | $58.72 Billion | 14.51% | 0.10x | $83.32 Million |
| CU Medical Systems Inc (115480) | $58.74 Billion | -5.46% | 0.76x | $5.90 Million |
About Meta Biomed Co. Ltd
Meta Biomed Co., Ltd. engages in the research and development, production, and marketing of dental and surgical materials in South Korea and internationally. The company's dental products include endodontics, endodontic materials, restorative materials, and bone graft materials. It also offers suture products comprising multifilament and monofilament products, as well as orthopedics; bone product… Read more